Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Aerpio completes dosing in TIME-2b study of AKB-9778

Emptied retinal venules due to arterial branch occlusion in diabetic retinopathy. Credit: Maria Sieglinda von Nudeldorf.



  • Aerpio Pharmaceuticals

Go Top